develop
effect
vaccin
prevent
influenza
particularli
highli
pathogen
avian
influenza
hpai
caus
influenza
viru
iav
subtyp
challeng
goal
studi
design
construct
two
recombin
influenza
vaccin
candid
fuse
hemagglutinin
fragment
either
fc
human
igg
foldon
plu
fc
evalu
immun
respons
crossprotect
diverg
strain
viru
result
show
two
recombin
vaccin
induc
strong
immun
respons
vaccin
mice
specif
react
protein
inactiv
heterolog
viru
protein
abl
crossneutr
infect
one
homolog
strain
clade
four
heterolog
strain
belong
clade
pseudovirus
well
three
heterolog
strain
clade
live
viru
importantli
immun
two
vaccin
candid
especi
provid
complet
crossclad
protect
highdos
lethal
challeng
differ
strain
viru
cover
clade
test
mous
model
studi
suggest
recombin
fusion
protein
particularli
could
develop
efficaci
univers
influenza
vaccin
provid
crossprotect
infect
diverg
strain
highli
pathogen
viru
citat
du
l
leung
vhc
zhang
x
zhou
j
chen
et
al
recombin
vaccin
fuse
foldon
human
igg
fc
induc
complet
crossclad
protect
diverg
virus
plo
one
influenza
epidem
pandem
caus
influenza
viru
iav
occur
frequent
first
influenza
pandem
st
centuri
emerg
novel
swineorigin
influenza
viru
soiv
caus
agent
origin
mexico
rapidli
spread
north
america
global
concern
howev
continu
outbreak
highli
pathogen
avian
influenza
hpai
influenza
subtyp
viru
circul
poultri
caus
hundr
human
diseas
sever
morbid
high
mortal
sinc
reemerg
http
wwwwhointcsrdiseaseavianinfluenzacountri
although
genet
analysi
isol
human
reveal
gene
avian
origin
limit
persontoperson
transmiss
virus
identifi
concern
futur
influenza
epidem
may
caus
new
viru
strain
deriv
mutat
andor
reassort
exist
influenza
virus
particularli
hpai
therefor
develop
effect
prevent
therapeut
measur
iav
particularli
avian
urgent
need
vaccin
import
strategi
counteract
influenza
pandem
current
effort
develop
hpai
vaccin
mainli
focus
inactiv
vaccin
demonstr
effect
anim
model
protect
infect
induc
neutral
antibodi
human
volunt
vaccin
candid
base
liveattenu
viru
viral
vector
viruslik
particl
vlp
dna
vaccin
recombin
protein
also
test
anim
model
even
evalu
clinic
trial
howev
rapid
mutat
hemagglutinin
ha
protein
hpai
viru
crossprotect
immun
vaccin
fundament
restrict
highli
limit
potenti
use
diverg
virus
fact
impli
futur
influenza
vaccin
develop
immunogen
abl
provid
broader
protect
variou
strain
viru
infect
may
achiev
upgrad
vaccin
formula
effect
adjuv
either
inactiv
liveattenu
iav
vaccin
design
novel
vaccin
compon
reli
conserv
sequenc
univers
epitop
viral
protein
matrix
protein
ha
nucleoprotein
np
updat
vaccin
deliveri
system
combin
viral
protein
compon
find
repres
signific
advanc
toward
develop
efficaci
influenza
vaccin
fc
igg
consid
import
fusion
tag
coexpress
sever
viral
protein
receptorbind
domain
rbd
sever
acut
respiratori
syndrom
coronaviru
sarscov
order
facilit
purif
subsequ
immunogen
protein
exampl
fusion
fc
protein
also
shown
increas
immunogen
fusion
protein
elicit
neutral
antibodi
respons
explain
abil
fc
promot
correct
fold
fusion
protein
follow
express
possibl
igg
fc
may
help
enhanc
bind
antigenpres
cell
apc
cell
line
express
fc
receptor
fcr
foldon
fd
sequenc
deriv
nativ
phage
fibritin
typic
incorpor
cterminu
collagenlik
protein
molecul
facilit
stabil
protein
trimer
oligom
indic
ctermin
fd
essenti
correct
trimer
fold
protein
studi
design
two
recombin
influenza
vaccin
base
recombin
protein
encod
viru
fuse
either
fc
human
igg
fc
thereaft
name
fc
fd
plu
fc
test
immun
respons
crossprotect
diverg
strain
viru
mous
model
develop
vaccin
candid
shown
induc
highli
potent
neutral
antibodi
protect
vaccin
mice
lethal
challeng
test
strain
viru
infect
contain
amino
acid
residu
fuse
infram
fc
fd
plu
fc
form
recombin
respect
fc
vector
signal
sequenc
recombin
protein
express
cultur
supernat
transfect
cell
fig
follow
purif
protein
supernat
protein
maintain
high
level
express
approxim
mg
obtain
ml
cultur
medium
purif
protein
analyz
sdspage
follow
coomassi
blue
stain
reactiv
determin
use
haspecif
monoclon
antibodi
mab
develop
laboratori
shown
fig
one
clear
band
observ
sampl
protein
analyz
sdspage
indic
highli
purifi
protein
could
obtain
transfect
cultur
supernat
purifi
recombin
protein
could
recogn
haspecif
mab
indic
western
blot
fig
reveal
high
specif
ha
antibodi
respons
sera
mice
vaccin
protein
evalu
elisa
shown
fig
protein
induc
igg
antibodi
respons
specif
purifi
protein
antibodi
titer
quickli
reach
high
level
first
vaccin
slightli
increas
boost
averag
endpoint
antibodi
titer
detect
mous
sera
collect
day
postlast
boost
fig
antibodi
level
detect
coat
elisa
plate
protein
without
fuse
fc
fd
elimin
antibodi
respons
potenti
induc
fusion
tag
fc
andor
fd
illustr
fig
sera
mice
vaccin
fusion
protein
particularli
react
strongli
protein
reach
endpoint
titer
demonstr
antibodi
respons
induc
express
protein
mainli
target
protein
shown
induc
antibodi
respons
found
sera
pb
control
mice
fig
data
suggest
express
protein
abl
elicit
high
titer
antibodi
respons
specif
protein
homogen
heterogen
virus
impli
high
immunogen
stimul
strong
humor
immun
respons
vaccin
mice
level
neutral
antibodi
vaccin
mice
evalu
cell
cultur
infect
four
clade
clade
pseudovirus
three
clade
clade
live
virus
tabl
fig
show
abl
induc
highli
potent
neutral
antibodi
respons
vaccin
mice
neutral
homolog
ahha
strain
also
heterolog
strain
pseudovirus
includ
hkha
qhha
xjha
result
also
demonstr
induc
antibodi
could
neutral
infect
heterolog
strain
live
virus
reach
highest
titer
viru
fig
addit
antibodi
could
inhibit
hemagglutin
three
live
virus
averag
hemagglutin
inhibit
hi
titer
fig
notabl
neutral
igg
detect
use
sera
mice
preimmun
day
vaccin
data
present
mean
standard
deviat
sd
five
mice
per
group
abil
igg
bind
protein
b
protein
without
fd
fc
c
inactiv
viru
respect
detect
use
mous
sera
day
postlast
vaccin
data
present
mean
five
mice
per
group
variou
dilut
point
antibodi
induc
protein
greater
induc
protein
show
significantli
higher
level
inhibit
infect
qhha
xjha
ahha
pseudovirus
contrast
pb
control
group
elicit
background
level
neutral
hi
antibodi
titer
test
pseudovirus
live
virus
fig
examin
crossprotect
effect
induc
protein
vaccin
mice
challeng
lethal
dose
ld
three
live
virus
day
postlast
vaccin
vaccin
mice
surviv
challeng
fig
fig
suggest
recombin
proteinbas
vaccin
may
complet
protect
mice
challeng
clade
strain
viru
mice
vaccin
also
surviv
challeng
wherea
mice
surviv
challeng
viru
fig
contrast
control
mice
inject
pb
surviv
challeng
virus
fig
result
demonstr
vaccin
two
fusion
protein
particularli
could
provid
crossclad
protect
diverg
strain
viru
infect
crossprotect
effect
elicit
protein
evalu
detect
viral
load
histopatholog
chang
lung
tissu
mice
collect
day
postviru
challeng
fig
reveal
viral
rna
undetect
mice
challeng
viru
high
level
viral
rna
copieslung
tissu
detect
control
mice
inject
pb
lung
tissu
mice
vaccin
also
exhibit
significantli
lower
level
viral
rna
pb
control
group
challeng
viru
respect
result
suggest
immun
induc
recombin
fusion
protein
abl
highli
suppress
viru
replic
vaccin
mous
lung
examin
h
estain
lung
tissu
viruschalleng
mice
demonstr
control
mice
inject
pb
develop
high
degre
histopatholog
damag
includ
seriou
interstiti
pneumonia
signific
inflamm
character
diffus
alveoli
collaps
predomin
lymphocyt
infiltr
epitheli
cell
degener
pulmonari
vascular
dilat
congest
focal
hemorrhag
exud
contrast
mice
receiv
vaccin
present
slightli
broaden
interstiti
space
littl
lymphocyt
infiltr
challeng
virus
cover
three
differ
clade
fig
antibodi
respons
provid
essenti
immun
infect
iav
main
surfac
protein
viru
ha
viru
serv
import
target
induct
specif
antibodi
neutral
activ
andor
protect
immun
hapi
viru
greater
contribut
viral
protein
na
np
induct
neutral
antibodi
andor
protect
habas
vaccin
shown
elicit
higher
titer
neutral
antibodi
prevent
influenza
viru
infect
test
anim
addit
human
clinic
trial
hacontain
vaccin
reveal
product
strong
broad
antibodi
respons
vaccin
inject
howev
current
influenza
vaccin
fail
provid
suffici
protect
infect
rapidli
mutat
influenza
virus
thu
novel
strategi
urgent
need
develop
vaccin
potenti
induc
crossclad
protect
multipl
strain
influenza
virus
fc
fragment
human
igg
previous
use
fusion
compart
improv
immunogen
propos
protein
underli
mechan
fc
fusion
proteinbas
vaccin
may
partial
due
protein
fc
could
bind
cell
fcr
latter
play
import
role
clearanc
viru
infect
protect
viru
challeng
via
fcrmediat
phagocytosi
inde
studi
demonstr
fccontain
influenza
vaccin
candid
abl
elicit
strong
antibodi
respons
neutral
diverg
strain
homolog
heterogen
pseudovirus
well
heterolog
live
viru
importantli
protein
could
elicit
potent
protect
immun
immun
mice
challeng
least
three
heterogen
strain
virus
addit
fc
anoth
compon
fd
could
also
consid
fusion
partner
help
increas
immunogen
recombin
vaccin
fd
trimer
motif
antibodi
titer
heterolog
strain
live
viru
titer
neutral
antibodi
determin
materi
method
present
mean
nt
five
mice
per
group
c
hi
antibodi
titer
heterolog
strain
live
viru
hi
titer
determin
highest
serum
dilut
indic
hemagglutin
activ
express
mean
sd
five
mice
per
group
maintain
nativ
trimer
conform
viral
envelop
protein
thu
enhanc
vaccin
efficaci
exampl
recombin
protein
express
nhr
fuse
fd
exhibit
trimer
conform
possess
potent
activ
broad
spectrum
strain
studi
found
induc
higher
neutral
antibodi
sever
strain
pseudovirus
live
viru
fig
stronger
protect
immun
challeng
strain
fig
result
confirm
fd
play
role
maintain
nativ
conform
neutral
epitop
oligomer
immunogen
induc
stronger
immun
respons
vaccin
anim
summari
design
construct
two
recombin
influenza
vaccin
candid
fusion
viral
fragment
major
target
influenza
vaccin
fc
human
igg
andor
fd
proofofconcept
studi
first
demonstr
fusion
viral
antigen
either
fc
alon
fd
fc
abl
induc
crossneutr
antibodi
strong
enough
variou
subtyp
viru
turn
could
provid
crossprotect
infect
differ
clade
viru
cell
cultur
vitro
mous
model
vivo
thu
data
suggest
possibl
develop
univers
influenza
vaccin
use
innov
strategi
fusion
viral
antigen
fd
fc
report
studi
futur
studi
need
elucid
mechan
crossprotect
immun
induc
propos
candid
vaccin
studi
anim
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
univers
hong
kong
experiment
protocol
follow
standard
oper
procedur
approv
biosafeti
anim
facil
approv
committe
use
live
anim
teach
research
univers
hong
kong
culatr
ref
gene
encod
amplifi
pcr
use
codonoptim
fulllength
ha
access
templat
insert
fc
express
vector
invivogen
san
diego
ca
encod
vaccin
fd
sequenc
deriv
bacteriophag
fibritin
fuse
cterminu
sequenc
pcr
overlap
primer
follow
insert
fc
express
vector
encod
vaccin
fig
recombin
protein
express
previous
describ
modif
briefli
sequenceconfirm
recombin
plasmid
transfect
cell
atcc
manassa
va
seed
h
prior
transfect
use
calcium
phosphat
method
cultur
medium
replac
fresh
optimem
medium
invitrogen
carlsbad
ca
h
later
supernat
collect
h
posttransfect
recombin
protein
supernat
purifi
protein
affin
chromatographi
ge
healthcar
piscataway
nj
accord
manufactur
instruct
purifi
protein
analyz
sdspage
western
blot
previous
describ
use
antiha
mab
develop
laboratori
briefli
purifi
protein
mg
separ
tricin
gel
invitrogen
transfer
nitrocellulos
membran
block
overnight
blot
incub
haspecif
mab
h
room
temperatur
three
wash
blot
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
invitrogen
h
room
temperatur
signal
visual
ecl
western
blot
substrat
reagent
amersham
hyperfilm
ge
healthcar
femal
balbc
mice
week
kept
hous
given
access
standard
pellet
feed
water
ad
libitum
mice
micegroup
subcutan
sc
primedvaccin
mgmous
purifi
protein
resuspend
pb
presenc
sigma
adjuv
system
sa
sigma
st
loui
mo
boost
twice
mgmous
immunogen
contain
sa
interv
control
mice
sc
inject
volum
pbssa
sera
collect
immun
day
posteach
vaccin
detect
ha
neutral
antibodi
mice
intranas
challeng
ld
three
clade
viru
ie
clade
clade
clade
respect
micegroup
day
last
vaccin
infect
mice
observ
daili
day
death
five
micegroup
sacrif
day
post
challeng
lung
sampl
collect
virolog
histopatholog
detect
antibodi
respons
evalu
elisa
collect
mous
sera
previous
describ
briefli
elisa
plate
precoat
respect
recombin
fusion
protein
protein
without
fd
fc
inactiv
viru
overnight
block
nonfat
milk
h
serial
dilut
mous
sera
ad
plate
incub
h
follow
four
wash
bound
antibodi
incub
hrpconjug
goat
antimous
igg
invitrogen
bethyl
laboratori
montgomeri
tx
h
reaction
visual
substrat
tmb
invitrogen
stop
h
absorb
nm
measur
elisa
plate
reader
tecan
san
jose
ca
titer
neutral
antibodi
detect
mous
sera
pseudoviru
neutral
assay
previous
describ
briefli
cell
cotransfect
plasmid
encod
envdefect
luciferaseexpress
genom
plasmid
encod
ha
homolog
ahha
heterolog
hkha
qhha
xjha
respect
use
calcium
phosphat
method
exogen
bacteri
neuraminidas
na
sigma
ad
h
later
supernat
harvest
h
posttransfect
singlecycl
infect
pseudoviruscontain
supernat
incub
serial
dilut
mous
sera
h
ad
cell
fresh
medium
ad
h
later
follow
lyse
cell
h
later
use
cell
lysi
buffer
promega
madison
wi
transfer
lysat
luminomet
plate
luciferas
substrat
promega
ad
plate
rel
luciferas
activ
determin
ultra
luminomet
tecan
neutral
ha
pseudoviru
calcul
present
nt
titer
neutral
antibodi
vaccin
mice
detect
neutral
assay
describ
previous
briefli
serial
twofold
dilut
mous
sera
respect
mix
plaqu
form
unit
pfu
incub
h
ad
mdck
cell
medium
replac
fresh
dmem
h
later
cell
cultur
continu
h
viral
cytopath
effect
cpe
observ
daili
record
day
postinfect
neutral
antibodi
titer
determin
base
highest
dilut
serum
complet
suppress
cpe
induc
viru
well
hi
assay
carri
previous
describ
modif
briefli
serial
dilut
mous
sera
incub
equal
volum
sz
viru
respect
h
room
temperatur
follow
addit
equal
volum
chicken
red
blood
cell
min
room
temperatur
hi
antibodi
titer
express
highest
serum
dilut
complet
inhibit
hemagglutin
activ
viral
rna
copi
lung
tissu
quantifi
qrtpcr
previous
describ
briefli
total
rna
lyse
lung
tissu
extract
use
rneasi
mini
kit
qiagen
valencia
ca
reversetranscrib
cdna
use
appli
superscript
ii
revers
transcriptas
invitrogen
viral
cdna
synthes
superscript
rt
ii
invitrogen
use
primer
agcaaaagc
realtim
pcr
perform
lightcycl
system
roch
appli
scienc
use
sybr
green
master
roch
genespecif
primer
pair
forward
primer
revers
primer
vn
forward
primer
revers
primer
sz
forward
primer
revers
primer
target
gene
differ
strain
viru
plasmid
contain
clone
gene
viru
appli
standard
lung
tissu
challeng
mice
immedi
fix
formalin
embed
paraffin
wax
section
mm
thick
made
mount
slide
histopatholog
chang
caus
viru
infect
examin
h
e
stain
view
light
microscop
previous
describ
valu
present
mean
sd
statist
signific
among
differ
vaccin
group
calcul
student
test
use
stata
statist
softwar
p
valu
less
consid
signific
